"Christian Pflaumer, a spokesperson for LENZ, told Axios in an email Thursday that the product is now available commercially in the U.S. after the company originally expected them to be available sometime before the end of the year."
"The drops are made of an aceclidine ophthalmic solution, which "is a new chemical entity in the United States and its FDA approval marks a global first in the treatment of presbyopia," LENZ Therapeutics says. The solution forces the iris sphincter muscle to relax and contract, creating a pinhole effect that increases the depth of focus and improves near vision, the company says. How it works: The VIZZ solution can start working within 30 minutes, the drugmaker says."
"Presbyopia is a fairly common condition that occurs between 40 and 50 years old, per the Centers for Disease Control and Prevention. It causes the loss of the ability to focus on nearby objects, making it hard to read a book or hold a newspaper farther away than needed, the CDC says. Like other refractive errors, presbyopia requires eyeglasses, contact lenses, or possibly surgery, per the CDC. Presbyopia generally isn't a top reason for LASIK surgery since reading glasses are a typical quick fix."
LENZ Therapeutics' VIZZ 1.44% eye drops are commercially available in the U.S. following FDA approval. The drops target presbyopia, an age-related loss of near focusing ability that commonly appears between ages 40 and 50 and affects hundreds of millions. VIZZ contains an aceclidine ophthalmic solution described as a new chemical entity that alters iris sphincter muscle activity to create a pinhole effect, increasing depth of focus and improving near vision. The solution can begin working within about 30 minutes. One drop per eye, taken once daily, can provide improved near vision for up to ten hours.
Read at Axios
Unable to calculate read time
Collection
[
|
...
]